London, UK – 29 March 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has invested in Tact.ai, the customer engagement company for life sciences. Tact.ai helps pharmaceutical companies work more effectively with health care professionals (HCPs) to deliver innovative medicines to patients faster. The investment is the fourth Life Sciences industry investment in the past six months for Tact.ai, following its $33 million USD fundraise last year.
29 March 2022
Founded by former Salesforce.com executive, Chuck Ganapathi, Tact’s customer engagement platform is designed for life sciences companies to take a holistic, outcome-centric approach to how they engage customers across all channels: face-to-face, phone, email, video, chat, and self-service. The platform innovations in mobile, artificial intelligence (AI) and user experience – which have been awarded six patents – enable field teams to boost productivity, personalize every interaction, allow HCPs to engage them on-demand and deliver a total experience to customers. The platform integrates multiple systems of record like CRM, email, calendar, next-best-action and 3rd party data into a unified system of engagement so teams get more out of existing technologies while creating better ways to work with the customer at every touchpoint.
“Systems-of-record like CRM alone are no longer sufficient in meeting the needs of today’s commercial and medical leaders,” said Chuck Ganapathi, Founder and CEO of Tact.ai. “We built a platform that gets the most out of existing technology investments and puts the knowledge of the customer’s needs in the palm of every team member’s hand so they can focus more on educating and building trusted relationships. We’re thrilled to have Hikma Ventures join our journey to reimagine customer engagement.”
“There is a growing need within the life sciences industry for hybrid engagement with health care providers and organizations, especially in light of the global pandemic, and the Tact platform provides a forward-thinking model for meeting that demand,” said Lana Ghanem, Managing Director of Hikma Ventures. “By offering a secure and seamless user experience that enables field teams to personalize each interaction with their customers and capture more insights, Tact is helping commercial and medical teams orchestrate the type of high-quality engagement that customers demand today. We’re impressed by Tact’s team experience and are excited to add it to our portfolio.”
Tact.ai will use the proceeds to support further expansion with leading pharma companies and to continue building the industry’s most customer-friendly engagement platform.